Advertisement

Primary Endocrine Therapy

  • Jenna Morgan
  • Lynda WyldEmail author
Chapter

Abstract

Use of endocrine therapy alone for the treatment of operable breast cancer, (primary endocrine therapy or PET) was first described in the 1980s and is a strategy adopted to varying degrees by different countries. It is a good option for the very frail or unfit older women with ER positive breast cancer. Selection for its use must take into account the probable life expectancy of the woman because secondary antioestrogen resistance develops after a median of 2–3 years. The biology of the tumour has a strong influence on response rates and aromatase inhibitors perform better than tamoxifen in this setting. Primary endocrine therapy is well tolerated and may avoid unnecessary morbidity for some women if selected appropriately. At present there are no evidence based selection guidelines but it is hoped these will be published soon once the Age Gap trial reports.

Keywords

Surgery Primary endocrine therapy Outcomes Risk assessment 

References

  1. 1.
    Johansson H, Terenius L, Thoren L. The binding of estradiol-17beta to human breast cancers and other tissues in vitro. Cancer Res. 1970;30(3):692–8.PubMedGoogle Scholar
  2. 2.
    Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973;1(5844):13–4.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet. 1985;1(8433):836–40.Google Scholar
  4. 4.
    Preece PE, Wood RA, Mackie CR, Cuschieri A. Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J (Clin Res Ed). 1982;284(6319):869–70.CrossRefGoogle Scholar
  5. 5.
    Horobin JM, Preece PE, Dewar JA, Wood RA, Cuschieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991;78(2):213–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Morgan J, Wyld L, Collins KA, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2014;(5):Art. No.: CD004272.Google Scholar
  7. 7.
    Wyld L, Garg DK, Kumar ID, Brown H, Reed MW. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer. 2004;90(8):1486–91.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M. Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. Br J Cancer. 2007;96(8):1197–203.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91(6):699–704.PubMedCrossRefGoogle Scholar
  10. 10.
    Jauhari Y, Gannon M, Medina J, Cromwell D, Horgan K, Dodwell D. National audit of breast cancer in older patients annual report. Healthcare quality improvement partnership. 2018.Google Scholar
  11. 11.
    Derks MGM, Liefers GJ, Kiderlen M, Hilling DE, Boelens PG, Walsh PM, van Eycken E, Siesling S, Broggio J, Wyld L, Trojanowski M, Chalubinska-Fendler J, Nowikiewicz T, Gonçalves AF, Audisio RA, van de Velde CJH, Bastiaannet E, on behalf of the EURECCA Breast Cancer Group. Variation in treatment and survival in older women with non-metastatic breast cancer in Europe: a population based study from the EURECCA Breast Cancer Group. Br J Cancer. 2018;119(1):121–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92(7):550–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Morgan J, Richards P, Ward S, Francis M, Lawrence G, Collins K, et al. Case-mix analysis and variation in rates of non-surgical treatment of older women with operable breast cancer. Br J Surg. 2015;102(9):1056–63.PubMedCrossRefGoogle Scholar
  14. 14.
    NICE. CG80 Early and locally advanced breast cancer: full guideline. 2009.Google Scholar
  15. 15.
    Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;13(4):e148–60.PubMedCrossRefGoogle Scholar
  16. 16.
    Morgan JL, Walters SJ, Collins K, Robinson TG, Cheung KL, Audisio R, et al. What influences healthcare professionals’ treatment preferences for older women with operable breast cancer? An application of the discrete choice experiment. Eur J Surg Oncol. 2017;43(7):1282–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Horgan K, Dodwell D, Cromwell D, Jauhari Y, Medina J, Tsang C. National audit of breast cancer in older patients part of the national clinical audit patient outcomes programme 2017 annual report. HQIP. 2017.Google Scholar
  18. 18.
    Morgan JL, Reed MW, Wyld L. Primary endocrine therapy as a treatment for older women with operable breast cancer – a comparison of randomised controlled trial and cohort study findings. Eur J Surg Oncol. 2014;40(6):676–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Gaskell DJ, Hawkins RA, de Carteret S, Chetty U, Sangster K, Forrest AP. Indications for primary tamoxifen therapy in elderly women with breast cancer. Br J Surg. 1992;79(12):1317–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Rao VS, Jameel JK, Mahapatra TK, McManus PL, Fox JN, Drew PJ. Surgery is associated with lower morbidity and longer survival in elderly breast cancer patients over 80. Breast J. 2007;13(4):368–73.PubMedCrossRefGoogle Scholar
  21. 21.
    Okunade G, Green AR, Ying M, Agrawal A, Paish EC, Aleskandrany M, et al. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. Crit Rev Oncol Hematol. 2009;72(1):76–82.PubMedCrossRefGoogle Scholar
  22. 22.
    Stotter A, Walker R. Tumour markers predictive of successful treatment of breast cancer with primary endocrine therapy in patients over 70 years old: a prospective study. Crit Rev Oncol Hematol. 2010;75(3):249–56.PubMedCrossRefGoogle Scholar
  23. 23.
    Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. Br J Cancer. 2011;105(12):1825–9.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Syed BM, Al-Khyatt W, Johnston SJ, Wong DW, Winterbottom L, Kennedy H, et al. Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre. Br J Cancer. 2011;104(9):1393–400.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Ayantunde A, Gomez M, Ruhomauly N, Hoque H. Primary endocrine therapy for hormone receptor positive breast cancer: a viable treatment alternative. Int J Tumor Ther. 2012;1(1):1–5.CrossRefGoogle Scholar
  26. 26.
    Hille U, Soergel P, Langer F, Schippert C, Makowski L, Hillemanns P. Aromatase inhibitors as solely treatment in postmenopausal breast cancer patients. Breast J. 2012;18(2):145–50.PubMedCrossRefGoogle Scholar
  27. 27.
    Llombart-Cussac A, Guerrero A, Galan A, Caranana V, Buch E, Rodriguez-Lescure A, et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol. 2012;14(2):125–31.PubMedCrossRefGoogle Scholar
  28. 28.
    Dordea M, Jones R, Nicolas AP, Sudeshna S, Solomon J, Truran P, et al. Surgery for breast cancer in the elderly--how relevant? Breast. 2011;20(3):212–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Akhtar SS, Allan SG, Rodger A, Chetty UD, Smyth JF, Leonard RC. A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail patients. Eur J Surg Oncol. 1991;17(1):30–5.PubMedGoogle Scholar
  30. 30.
    Bergman L, van Dongen J, van Ooijen B, van Leeuwen E. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat. 1995;34:77–83.PubMedCrossRefGoogle Scholar
  31. 31.
    Selli C, Dixon JM, Sims AH. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res. 2016;18(1):118.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, et al. Evaluating the 21-gene assay Recurrence Score(R) as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. Int J Clin Oncol. 2014;19(4):607–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Gellert P, Segal CV, Gao Q, Lopez-Knowles E, Martin LA, Dodson A, et al. Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. Nat Commun. 2016;7:13294.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, et al. Accurate prediction and validation of response to endocrine therapy in breast cancer. J Clin Oncol. 2015;33(20):2270–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11(2 Pt 2):951s–8s.PubMedGoogle Scholar
  37. 37.
    Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumuller M, et al. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget. 2018;9(23):16389–99.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Cell-free DNA integrity for the monitoring of breast cancer: future perspectives? World J Clin Oncol. 2018;9(2):26–32.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105(Suppl 1):33–43.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Janicke F, Bastert G, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;8:62.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16.PubMedCrossRefGoogle Scholar
  44. 44.
    Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103.PubMedCrossRefGoogle Scholar
  45. 45.
    Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–54.PubMedCrossRefGoogle Scholar
  46. 46.
    Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiowka M, Hewson N, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II first study. J Clin Oncol. 2015;33(32):3781–7.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005.PubMedCrossRefGoogle Scholar
  48. 48.
    Early Breast Cancer Trialists’ Collaborative G. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–61.CrossRefGoogle Scholar
  49. 49.
    Ramos-Esquivel A, Hernandez-Steller H, Savard MF, Landaverde DU. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. Breast Cancer. 2018;25:479–88.PubMedCrossRefGoogle Scholar
  50. 50.
    Chow LWC, Morita S, Chow CYC, Ng WK, Toi M. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value. Endocr Relat Cancer. 2018;25(2):123–30.PubMedCrossRefGoogle Scholar
  51. 51.
    Hooper S, Hill A, Kennedy S, Dijkstra B, Kelly L, McDermott E, et al. Tamoxifen as the primary treatment in elderly patients with breast cancer. Ir J Med Sci. 2002;171(1):28–30.PubMedCrossRefGoogle Scholar
  52. 52.
    Hamaker M, Bastiaannet E, Evers D, Van de Water W, Smorenburg C, Maartense E, et al. Omission of surgery in elderly patients with early stage breast cancer. Eur J Cancer. 2013;49:545–52.PubMedCrossRefGoogle Scholar
  53. 53.
    Rai S, Stotter A. Management of elderly patients with breast cancer: the time for surgery. ANZ J Surg. 2005;75(10):863–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Lavelle K, Sowerbutts AM, Bundred N, Pilling M, Degner L, Stockton C, et al. Is lack of surgery for older breast cancer patients in the UK explained by patient choice or poor health? A prospective cohort study. Br J Cancer. 2014;110(3):573–83.PubMedCrossRefGoogle Scholar
  55. 55.
    Stotter A, Reed MW, Gray LJ, Moore N, Robinson TG. Comprehensive geriatric assessment and predicted 3-year survival in treatment planning for frail patients with early breast cancer. Br J Surg. 2015;102(5):525–33; discussion 33.PubMedCrossRefGoogle Scholar
  56. 56.
    Ward SE, Richards P, Morgan J, Holmes GR, Broggio J, Collins K, Reed MW, Wyld L. Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer specific survival. Br J Surg. 2018;105:1454–63.PubMedCrossRefGoogle Scholar
  57. 57.
    Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M. Non-standard management of breast cancer increases with age in the UK: a population based cohort of women >= 65 years. Br J Cancer. 2007;96(8):1197–203.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Lavelle K, Moran A, Howell A, Bundred N, Campbell M, Todd C. Older women with operable breast cancer are less likely to have surgery. Br J Surg. 2007;94(10):1209–15.PubMedCrossRefGoogle Scholar
  59. 59.
    Ali A, Greenberg D, Wishart G, Pharoah P. Patient and tumour characteristics, management, and age-specific survival in women with breast cancer in the East of England. Br J Cancer. 2011;104(4):564–70.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Morgan JL, Collins K, Robinson TG, Cheung KL, Audisio R, Reed MW, et al. Healthcare professionals’ preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer. Eur J Surg Oncol. 2015;41(9):1234–42.PubMedCrossRefGoogle Scholar
  61. 61.
    Lavelle K, Downing A, Thomas J, Lawrence G, Forman D, Oliver SE. Are lower rates of surgery amongst older women with breast cancer in the UK explained by co-morbidity? Br J Cancer. 2012;107(7):1175–80.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Prince M, Knapp M, Guerchet M, McCrone P, Prina M, Comas-Herrera A, et al. Dementia UK: second edition – overview. London: Alzheimer’s Society UK; 2014.Google Scholar
  63. 63.
    Office for National Statistics. Deaths registered in England and Wales (Series DR), 2013. London; 2014.Google Scholar
  64. 64.
    Moller J, Cluitmans P, Rasmussen L, Houx P, Rasmussen H, Canet J, et al. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet. 1998;351(9106):857–61.PubMedCrossRefGoogle Scholar
  65. 65.
    Allan S, Rodger A, Smyth J, Leonard R, Chetty U, Patrick A, et al. Tamoxifen as primary-treatment of breast-cancer in elderly or frail patients – a practical management. Br Med J. 1985;290(6465):358.CrossRefGoogle Scholar
  66. 66.
    Foudraine N, Verhoef L, Burghouts J. Tamoxifen as sole therapy for primary breast cancer in the elderly patient. Eur J Cancer. 1992;28(4/5):900–3.CrossRefGoogle Scholar
  67. 67.
    Osborn G, Jones M, Champ C, Gower-Thomas K, Vaughan-Williams E. Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer? Ann R Coll Surg Engl. 2011;93(4):286–9.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Gorin S, Heck J, Albert S, Hershman D. Treatment for breast cancer in patients with Alzheimer’s disease. J Am Geriatr Soc. 2005;53:1897–904.PubMedCrossRefGoogle Scholar
  69. 69.
    Robb C, Boulware D, Overcash J, Extermann M. Patterns of care and survival in cancer patients with cognitive impairment. Crit Rev Oncol Hematol. 2010;74:218–24.PubMedCrossRefGoogle Scholar
  70. 70.
    Fallowfield L. Quality of life in the elderly woman with breast cancer treated with tamoxifen and surgery or tamoxifen alone. J Women’s Health. 1994;3:17–20.CrossRefGoogle Scholar
  71. 71.
    Shimozuma K, Ganz PA, Petersen L, Hirji K. Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery. Breast Cancer Res Treat. 1999;56(1):45–57.PubMedCrossRefGoogle Scholar
  72. 72.
    Grond S, Zech D, Diefenbach C, Radbruch L, Lehmann KA. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996;64(1):107–14.PubMedCrossRefGoogle Scholar
  73. 73.
    Kuehn T, Klauss W, Darsow M, Regele S, Flock F, Maiterth C, et al. Long-term morbidity following axillary dissection in breast cancer patients--clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat. 2000;64(3):275–86.PubMedCrossRefGoogle Scholar
  74. 74.
    Parks RM, Hall L, Tang SW, Howard P, Lakshmanan R, Winterbottom L, et al. The potential value of comprehensive geriatric assessment in evaluating older women with primary operable breast cancer undergoing surgery or non-operative treatment--a pilot study. J Geriatr Oncol. 2015;6(1):46–51.PubMedCrossRefGoogle Scholar
  75. 75.
    Shrestha A, Martin C, Burton M, Holmes G, Ward S, Collins K, Audisio R, Chater T, Pemberton K, Robinson T, Cheung KL, Ring A, Walters S, Reed M, Green T, Revell D, Gath J, Wyld L. Comparison of quality of life of older women treated with surgery or primary endocrine therapy for early breast cancer: propensity score matched analysis of a large prospective multicentre cohort study. Eur J Cancer. 2018;92:S3–4.CrossRefGoogle Scholar
  76. 76.
    Husain LS, Collins K, Reed M, Wyld L. Choices in cancer treatment: a qualitative study of the older women’s (>70 years) perspective. Psychooncology. 2008;17(4):410–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;(1):CD004272.Google Scholar
  78. 78.
    Burton M, Collins KA, Lifford KJ, Brain K, Wyld L, Caldon L, et al. The information and decision support needs of older women (>75 yrs) facing treatment choices for breast cancer: a qualitative study. Psychooncology. 2015;24(8):878–84.PubMedCrossRefGoogle Scholar
  79. 79.
    Burton M, Kilner K, Wyld L, Lifford KJ, Gordon F, Allison A, et al. Information needs and decision-making preferences of older women offered a choice between surgery and primary endocrine therapy for early breast cancer. Psychooncology. 2017;26:2094–100.PubMedCrossRefGoogle Scholar
  80. 80.
    Collins K, Lifford K, Durton M, Reed M, Wyld L et al. Bridging the age gap in breast cancer: evaluation of decision support interventions for older women with operable breast cancer: protocol for a cluster randomised controlled trial. BMJ Open. 2017;7(7):e015133.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Schonberg MA, Birdwell RL, Bychkovsky BL, Hintz L, Fein-Zachary V, Wertheimer MD, et al. Older women’s experience with breast cancer treatment decisions. Breast Cancer Res Treat. 2014;145(1):211–23.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Oncology and MetabolismUniversity of Sheffield Medical SchoolSheffieldUK
  2. 2.Doncaster and Bassetlaw Teaching Hospitals NHS Foundation TrustDoncasterUK

Personalised recommendations